PUBLISHER: TechNavio | PRODUCT CODE: 1937511
PUBLISHER: TechNavio | PRODUCT CODE: 1937511
Global Antiemetic Drug Market 2026-2030
The global antiemetic drug market is forecasted to grow by USD 1918.6 mn during 2025-2030, accelerating at a CAGR of 6.4% during the forecast period. The report on the global antiemetic drug market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of cancer and demand for chemotherapy induced nausea, advancements in formulation technologies and delivery systems, expansion into non-oncology indications for motion sickness.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2026 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 6.2% |
| CAGR | 6.4% |
| Incremental Value | $1918.6 mn |
Technavio's global antiemetic drug market is segmented as below:
By Drug Class
- 5-HT 3 receptor antagonist
- Dopamine antagonist
- NK 1 receptor antagonist
- Cannabinoid receptor antagonist
- Others
By Application
- Chemotherapy
- Surgery
- Gastroenteritis
- Others
By Route Of Administration
- Injectable
- Oral
- Transdermal
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Russia
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the increasing adoption of ready to use and long-acting injectable formulations as one of the prime reasons driving the global antiemetic drug market growth during the next few years. Also, strategic partnerships and acquisitions to expand portfolios and regulatory encouragement for multi mechanism will lead to sizable demand in the market.
The report on the global antiemetic drug market covers the following areas:
- Global antiemetic drug market sizing
- Global antiemetic drug market forecast
- Global antiemetic drug market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global antiemetic drug market vendors that include Acacia Pharma Group Plc, Accord Healthcare Ltd., Astellas Pharma Inc., B.Braun SE, Baxter International Inc., Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius Kabi AG, GlaxoSmithKline Plc, Helsinn Healthcare SA, Merck and Co. Inc., Novartis AG, Pfizer Inc., Sandoz Group AG, Sanofi SA, Sun Pharmaceutical Industries, Takeda Pharmaceutical Ltd., Teva Pharmaceutical Ltd., Viatris Inc.. Also, the global antiemetic drug market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Drug Class
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Antiemetic Drug Market 2020 - 2024
- Historic Market Size - Data Table on Global Antiemetic Drug Market 2020 - 2024 ($ million)
- 5.2 Drug Class segment analysis 2020 - 2024
- Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
- 5.3 Application segment analysis 2020 - 2024
- Historic Market Size - Application Segment 2020 - 2024 ($ million)
- 5.4 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Antiemetic Drug Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Drug Class
- 8.1 Market segments
- 8.2 Comparison by Drug Class
- 8.3 5-HT 3 receptor antagonist - Market size and forecast 2025-2030
- 8.4 Dopamine antagonist - Market size and forecast 2025-2030
- 8.5 NK 1 receptor antagonist - Market size and forecast 2025-2030
- 8.6 Cannabinoid receptor antagonist - Market size and forecast 2025-2030
- 8.7 Others - Market size and forecast 2025-2030
- 8.8 Market opportunity by Drug Class
- Market opportunity by Drug Class ($ million)
9 Market Segmentation by Application
- 9.1 Market segments
- 9.2 Comparison by Application
- 9.3 Chemotherapy - Market size and forecast 2025-2030
- 9.4 Surgery - Market size and forecast 2025-2030
- 9.5 Gastroenteritis - Market size and forecast 2025-2030
- 9.6 Others - Market size and forecast 2025-2030
- 9.7 Market opportunity by Application
- Market opportunity by Application ($ million)
10 Market Segmentation by Route of Administration
- 10.1 Market segments
- 10.2 Comparison by Route of Administration
- 10.3 Injectable - Market size and forecast 2025-2030
- 10.4 Oral - Market size and forecast 2025-2030
- 10.5 Transdermal - Market size and forecast 2025-2030
- 10.6 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.4.7 Russia - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 Japan - Market size and forecast 2025-2030
- 12.5.3 India - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.5.7 Singapore - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Australia - Market size and forecast 2025-2030
- 12.6.2 Brazil - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 South Africa - Market size and forecast 2025-2030
- 12.6.5 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.6 Turkey - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Rising prevalence of cancer and demand for chemotherapy induced nausea
- Advancements in formulation technologies and delivery systems
- Expansion into non-oncology indications for motion sickness
- 13.2 Market challenges
- Adverse effects and safety concerns associated with antiemetic drugs
- Intense generic competition and price erosion
- Management of breakthrough and refractory nausea
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Increasing adoption of ready to use and long-acting injectable formulations
- Strategic partnerships and acquisitions to expand portfolios
- Regulatory encouragement for multi mechanism
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 B.Braun SE
- B.Braun SE - Overview
- B.Braun SE - Product / Service
- B.Braun SE - Key news
- B.Braun SE - Key offerings
- SWOT
- 15.5 Baxter International Inc.
- Baxter International Inc. - Overview
- Baxter International Inc. - Business segments
- Baxter International Inc. - Key news
- Baxter International Inc. - Key offerings
- Baxter International Inc. - Segment focus
- SWOT
- 15.6 Cadila Pharmaceuticals Ltd.
- Cadila Pharmaceuticals Ltd. - Overview
- Cadila Pharmaceuticals Ltd. - Product / Service
- Cadila Pharmaceuticals Ltd. - Key offerings
- SWOT
- 15.7 Dr. Reddys Laboratories Ltd.
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key news
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Segment focus
- SWOT
- 15.8 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.9 Fresenius Kabi AG
- Fresenius Kabi AG - Overview
- Fresenius Kabi AG - Product / Service
- Fresenius Kabi AG - Key offerings
- SWOT
- 15.10 Helsinn Healthcare SA
- Helsinn Healthcare SA - Overview
- Helsinn Healthcare SA - Product / Service
- Helsinn Healthcare SA - Key offerings
- SWOT
- 15.11 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 15.12 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.13 Sandoz Group AG
- Sandoz Group AG - Overview
- Sandoz Group AG - Product / Service
- Sandoz Group AG - Key offerings
- SWOT
- 15.14 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.15 Sun Pharmaceutical Industries
- Sun Pharmaceutical Industries - Overview
- Sun Pharmaceutical Industries - Product / Service
- Sun Pharmaceutical Industries - Key news
- Sun Pharmaceutical Industries - Key offerings
- SWOT
- 15.16 Takeda Pharmaceutical Ltd.
- Takeda Pharmaceutical Ltd. - Overview
- Takeda Pharmaceutical Ltd. - Product / Service
- Takeda Pharmaceutical Ltd. - Key news
- Takeda Pharmaceutical Ltd. - Key offerings
- SWOT
- 15.17 Teva Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd. - Overview
- Teva Pharmaceutical Ltd. - Business segments
- Teva Pharmaceutical Ltd. - Key news
- Teva Pharmaceutical Ltd. - Key offerings
- Teva Pharmaceutical Ltd. - Segment focus
- SWOT
- 15.18 Viatris Inc.
- Viatris Inc. - Overview
- Viatris Inc. - Business segments
- Viatris Inc. - Key news
- Viatris Inc. - Key offerings
- Viatris Inc. - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
